Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2017 at "Clinical and Translational Oncology"
DOI: 10.1007/s12094-017-1799-7
Abstract: PurposeAberrant activation of MET as a result of exon 14-skipping (METex14) mutations or gene amplification is an oncogenic mechanism in non-small cell lung carcinoma (NSCLC) and a potential therapeutic target. The purpose of this study… read more here.
Keywords: met alterations; cell lung; metex14 mutations; non small ... See more keywords
Abstract CT034: Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study)
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Research"
DOI: 10.1158/1538-7445.am2022-ct034
Abstract: Background: METex14 mutations was reported in 3~4% of NSCLC patients and became a new target in the treatment of NSCLC. SCC244 is a highly selective and potent oral MET inhibitor. This is the first report… read more here.
Keywords: metex14 mutations; nsclc patients; phase study; treatment ... See more keywords
Clinical and genomic analysis of non-small cell lung cancer (NSCLC) patients with MET exon14 skipping (METex14) mutations and responses to anti-MET therapy.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.9613
Abstract: 9613Background: MET is a validated oncogene for molecular targeted therapy in non-small-cell lung cancer (NSCLC), and METex14 mutations result in MET overexpression. Studies with MET-targeting ther... read more here.
Keywords: non small; cell lung; cancer nsclc; metex14 mutations ... See more keywords